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responsibility of XAbstract A rapid and sensitive liquid chromatography–tandem mass spectrometric (LC–MS/MS)
assay method has been developed and fully validated for the simultaneous quantiﬁcation of
telmisartan and amlodipine in human plasma. Carbamazepine was used as an internal standard.
Analytes and the internal standard were extracted from human plasma by solid-phase extraction
technique using Waters Oasiss HLB 1 cm3 (30 mg) extraction cartridge. The reconstituted samples
were chromatographed on a Hypurity advance C18 column (50 mm 4.6 mm, 5 mm) using a
mixture of acetonitrile–5 mM ammonium acetate buffer (pH-4.0) (50:50, v/v) as the mobile phase at
a ﬂow rate of 0.8 mL/min. The calibration curve obtained was linear (rZ0.99) over the
concentration range of 2.01–400.06 ng/mL for telmisartan and 0.05–10.01 ng/mL for amlodipine.
Method validation was performed as per FDA guidelines and the results met the acceptance
criteria. A run time of 2.5 min for each sample made it possible to analyze more than 400 human
plasma samples per day. The proposed method was found to be applicable to clinical studies.




i’an Jiaotong University.1. Introduction
Telmisartan (Fig. 1) is a highly selective angiotensin II type 1
receptor antagonist, widely used in the treatment of hypertension
and heart failure [1–3]. It can selectively block the angiotensin
type 1 receptor without affecting other receptor systems involved
in cardiovascular regulation. Amlodipine (Fig. 1), a dihydropyr-
idine calcium antagonist, is prescribed for the treatment of angina
and hypertension. Amlodipine is a peripheral arterial vasodilator
that acts directly on vascular smooth muscle to cause a reduction

















Figure 1 Chemical structures of telmisartan (A), amlodipine (B),
and carbamazepine (C).
V.B. Ravi et al.320A combination of antihypertensive agents can better control
blood pressure and reduce the number and severity of side effects
than a monotherapy. Both angiotensin II type 1 receptor blockers
and calcium channel blockers were shown to be efﬁcacious in
reducing cardiovascular risk. Telmisartan and amlodipine ﬁxed
dose combinations have been demonstrated in numerous clinical
trials to be highly effective in lowering blood pressure and suggest
that the combined use might be more effective in treating hyper-
tension than a monotherapy [7,8]. Twynstas, a new single pill
combination therapy of telmisartan and amlodipine, is approved
by US FDA for the treatment of hypertension.
As per the literature, several LC–MS/MS methods have been
reported for the determination of telmisartan [9–16] and amlodi-
pine [17–27] individually or with other drugs in biological samples.
To date, no LC–MS/MS method has been reported for the
simultaneous determination of telmisartan and amlodipine in
human plasma. For pharmacokinetic and bioequivalence studies
of telmisartan associated with amlodipine, it is recommended to
perform the quantitation of telmisartan and amlodipine simulta-
neously. The present work describes a simple, selective and sensitive
method, which employs a simple solid-phase extraction technique
for sample preparation and liquid chromatography with electro-
spray ionization-tandem mass spectrometry for simultaneous
quantitation of telmisartan and amlodipine in human plasma.
The application of this assay method to a clinical pharmacokinetic
study in healthy male volunteers following oral single pill admin-
istration of telmisartan and amlodipine is described.2. Experimental
2.1. Chemicals and reagents
The reference samples of telmisartan (99.89%) and amlodipine
(99.59%) were purchased from Neucon Pharma Ltd. (Goa,India). Carbamazepine (99.27%) used as an internal standard
(IS) in this study, was obtained from Hetero Labs Ltd.
(Hyderabad, India). Water used for the LC–MS/MS analysis
was prepared from Milli Q water puriﬁcation system procured
from Millipore (Bangalore, India). Acetonitrile and methanol
were of HPLC grade and purchased from J.T. Baker (Phillips-
burg, USA). Analytical grade ammonium acetate and acetic acid
were purchased from Merck (Mumbai, India). Oasiss HLB
1 cm3 (30 mg) extraction cartridge was purchased from Waters
Corporation (Milford, Massachuselts, USA). The control K2-
EDTA human plasma sample was procured from Doctor’s
Pathological Laboratory (Hyderabad, India).2.2. Instrumentation and chromatographic conditions
An HPLC system (Shimadzu, Kyoto, Japan) consisting of a
Hypurity advance C18 column (50 mm 4.6 mm, 5 mm;
Thermo Electron Corporation, Bellefonte, PA), a binary LC-
20AD prominence pump, an autosampler (SIL-HTc) and a
solvent degasser (DGU-20A3) was used for the study. Ali-
quots of the processed samples (20 mL) were injected into the
column, which was kept at 30 1C. The isocratic mobile phase,
a mixture of acetonitrile and 5 mM ammonium acetate (pH-
4.0) (50:50, v/v) was delivered at 0.8 mL/min into the electro-
spray ionization chamber of the mass spectrometer. Quantita-
tion was achieved with MS–MS detection in positive ion mode
for both the analytes and the internal standard using a MDS
Sciex API-4000 mass spectrometer (Foster City, CA, USA)
equipped with a TurboionsprayTM interface at 500 1C. The ion
spray voltage was set at 5500 V. The source parameters, viz.
the nebulizer gas, curtain gas, auxiliary gas and collision gas
were set at 45, 20, 45 and 10 psi, respectively. The compound
parameters viz. the declustering potential (DP), collision
energy (CE), entrance potential (EP) and collision cell exit
potential (CXP) were 80, 65, 10, 15 V for telmisartan, 50, 15,
10, 12 V for amlodipine and 75, 27, 10, 5 V for the IS.
Detection of the ions was carried out in the multiple-reaction
monitoring mode (MRM), by monitoring the transition pairs
of m/z 515.2 precursor ion to the m/z 276.2 for telmisartan,
m/z 409.3 precursor ion to the m/z 238.2 for amlodipine and
m/z 237.2 precursor ion to the m/z 194.1 product ion for the
IS. Quadrupoles Q1 and Q3 were set on unit resolution. The
analysis data obtained were processed by Analyst softwareTM
(version 1.4.2).2.3. Preparation of standard solutions
Primary stock solutions of telmisartan and amlodipine for
preparation of standard calibration curve and quality control
(QC) samples were prepared from separate weighing. The
stock solutions of telmisartan (1000 mg/mL) and amlodipine
(100 mg/mL) were prepared in methanol and these stocks were
stored at 2–8 1C; they were found to be stable for 10 days.
From these stock solutions, appropriate dilutions were made
using a mixture of acetonitrile and water (50:50, v/v) as a
diluent, to produce working standard solutions of telmisartan
and amlodipine. The primary stock solution of carbamazepine
(1000 mg/mL) was prepared in methanol. A working concen-
tration of the internal standard (500 ng/mL) solution was
prepared in the diluent (acetonitrile and water, 50:50, v/v).
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control samples
Calibration samples were prepared by spiking 950 mL of control
human plasma with the appropriate working standard solution
of the each analyte (25 mL dilution of telmisartan and 25 mL of
amlodipine). Calibration curve standards consisting of a set of
ten non-zero concentrations ranging from 2.01 to 400.06 ng/mL
for telmisartan and 0.05 to 10.01 ng/mL for amlodipine were
prepared. Samples for the determination of precision and
accuracy were prepared by spiking control human plasma in
bulk with telmisartan and amlodipine at appropriate concen-
trations and 350 mL plasma aliquots were distributed into
different tubes. The QC samples prepared for each analyte
are: for telmisartan—2.05 lower limit of quantiﬁcation,
(LLOQ), 6.02 (LQC), 200.79 (MQC) and 340.32 ng/mL
(HQC); and amlodipine—0.05 (LLOQ), 0.15 (LQC), 5.04
(MQC) and 8.54 ng/mL (HQC). All the samples were stored
at 7075 1C for subsequent use.
2.5. Sample processing
A 250 mL aliquot of human plasma sample was mixed with
25 mL of the internal standard working solution (500 ng/mL of
carbamazepine). To this, 250 mL of Milli Q water was added
after vortex mixing for 10 s. The sample mixture was loaded
onto a Oasiss HLB 1 cm3 (30 mg) extraction cartridge that
was pre-conditioned with 1.0 mL of methanol followed by
1.0 mL water. The extraction cartridge was washed with
1.0 mL of water. Telmisartan, amlodipine and carbamazepine
were eluted with 0.5 mL of mobile phase. Aliquot of 20 mL of
the extract was injected into the LC–MS/MS system.
2.6. Method validation
A thorough validation of the method was carried out as per the
US FDA guidelines [28]. The method was validated for selectiv-
ity, sensitivity, matrix effect, linearity, precision, accuracy, recov-
ery, dilution integrity and stability. Selectivity of the method was
assessed by analyzing six blank human plasma matrix samples.
The responses of the interfering substances or background noises
at the retention time of the telmisartan and amlodipine are
acceptable if they are less than 20% of the response of the lowest
standard curve point or LLOQ. The responses of the interfering
substances or background noise at the retention time of the
internal standard are acceptable if they are less than 5% of the
response of the working internal standard.
Sensitivity was established from the background noise or
response from six spiked LLOQ samples. The six replicates
should have a precision of r20% and an accuracy of 720%.
Matrix effect is investigated to ensure that precision, selectivity
and sensitivity are not compromised by the matrix. Matrix
effect was checked with six different lots of K2-EDTA plasma.
Three replicate samples each of LQC and HQC were prepared
from different lots of plasma (36 QC samples in total).
Linearity was tested for telmisartan and amlodipine in
the concentration range of 2.01–400.06 and 0.05–10.01 ng/
mL, respectively. For the determination of linearity, standard
calibration curves containing at least 10 points (non-zero
standards) were plotted and checked. In addition, blank
plasma samples were also analyzed to conﬁrm the absence ofdirect interferences, but these data were not used to construct
the calibration curve. The acceptance limit of accuracy for
each of the back-calculated concentrations is 715% except
LLOQ, where it is 720%. For a calibration run to be
accepted at least 67% of the standards, the LLOQ and upper
limit of quantiﬁcation (ULOQ) are required to meet the
acceptance criterion, otherwise the calibration curve was
rejected. Five replicate analyses were performed on each
calibration standard. The samples were run in the order from
low to high concentration.
Intra-day assay precision and accuracy were determined
by analyzing six replicates at ﬁve different QC levels in the
same day on two runs. Inter-day assay precision and accuracy
were determined by analyzing six replicates at four different
QC levels on ﬁve different runs. The acceptance criteria
included accuracy within 715% deviation (SD) from
the nominal values, except LLOQ QC, where it should
be 720% and a precision of r15% relative standard
deviation (RSD), except for LLOQ QC, where it should be
r20%. Whereas batch acceptance criteria included 67% for
over all quality control samples and 50% at each level
respectively.
Recovery of the analytes from the extraction procedure was
determined by comparing the peak areas of the analytes in
spiked plasma samples (six each of low, middle, and high QC
samples) with those of the analytes in samples prepared by
spiking the extracted drug-free plasma samples with the same
amounts of the analytes at the step immediately prior to
chromatography. Similarly, recovery of the IS was determined
by comparing the mean peak areas of the extracted QC
samples (n¼6) with those of the IS in samples prepared by
spiking the extracted drug-free plasma samples with the same
amounts of the IS (500 ng/mL) at the step immediately prior
to chromatography.
The dilution integrity exercise is performed with an aim to
validate the dilution test to be carried out on higher analyte
concentrations above the ULOQ during real time analysis of
subject samples. Dilution integrity experiment was carried out
at 1.6 times the ULOQ concentration for both the analytes.
Six replicates each of 1/2 and 1/4th concentrations were
prepared and their concentrations were calculated by applying
the dilution factors 2 and 4.
Stability tests were conducted to evaluate the analyte
stability in stock solutions and in plasma samples under
different conditions. The stock solution stability at room
temperature and refrigerated conditions (2–8 1C) was per-
formed by comparing the area response of the analytes
(stability samples) with the response of the sample prepared
from fresh stock solution. Bench top stability (10 h), processed
samples stability (autosampler stability for 48 h, wet extract
stability for 40 h and reinjection stability for 24 h), freeze–
thaw stability (four cycles), and long-term stability (30 days)
were performed at LQC and HQC levels using six replicates at
each level. Samples were considered to be stable if assay values
were within the acceptable limits of accuracy (715% SD) and
precision (r15% RSD).2.7. Pharmacokinetic study design
A pharmacokinetic study was performed in healthy male
subjects (n¼6). The ethics committee approved the protocol
V.B. Ravi et al.322and the volunteers provided with informed written consent.
Blood samples (1 mL) were collected following oral adminis-
tration of 80/10 mg ﬁxed dose combination tablet of telmi-
sartan and amlodipine at pre-dose and 0.25, 0.5, 0.75, 1, 1.25,
1.5, 2, 3, 4, 5, 6, 7, 7.5, 8, 8.5, 9, 10, 12, 16, 24, 36, 48, 72 and
96 h, in K2-EDTA vacutainer collection tubes (BD, Franklin,
NJ, USA). The tubes were centrifuged at 3200 rpm for 10 min
at 4 1C and the plasma was collected. Immediately after
collection, the plasma samples were stored at –70 1C till their
use. Plasma samples were spiked with the IS and processed as
per the extraction procedure described earlier. Along with the
clinical samples, the QC samples at low, middle and high
concentration levels were assayed in triplicate and were
distributed among the unknown samples in the analytical
run; not more than 33% of the QC samples were greater than
715% of the nominal concentration. Plasma concentration–
time proﬁle of each analyte was analyzed by non-compart-
mental method using WinNonlin Version 5.1.3. Results
3.1. Mass spectrometry
Mass parameters were tuned in both positive and negative
ionization modes for the analytes. Good response was
achieved in positive ionization mode. Data from the MRM
mode were considered to obtain better selectivity. Protonated
form of each analyte and IS [MþH]þ ion was the parent ion in
the Q1 spectrum and was used as the precursor ion to obtain
Q3 product ion spectra. The most sensitive mass transition was
monitored from m/z 515.2 to 276.2 for telmisartan, m/z 409.3
to 238.2 for amlodipine and from m/z 237.2 to 194.1 for
the IS. As earlier publications have discussed the details of
fragmentation patterns of telmisartan [9], amlodipine [17] and
the IS [29], we are not presenting the data pertaining to this.
3.2. Method development
The chromatographic conditions, especially the composition of
mobile phase, were optimized through several trials to achieve
good resolution and symmetric peak shapes for the analytes as
well as a short run time. Separation was attempted using various
combinations of acetonitrile and buffer with varying contents of
each component on different columns like C8 and C18 of different
makes like Chromolith, Hypersil, Hypurity advance, Zorbax,
Kromasil and Intertsil. It was found that a mixture of acetonitrile
and 5 mM ammonium acetate (pH-4.0) (50:50, v/v) could achieve
this purpose and was ﬁnally adopted as the mobile phase.
Hypurity advance C18 (50 mm 4.6 mm, 5 mm) gave a good
peak shape and response even at LLOQ level for both the
analytes and the IS. The retention time of telmisartan, amlodipine
and the IS was low enough (1.52, 0.65 and 1.23 min) allowing a
small run time of 2.5 min.
A simple solid-phase extraction (SPE) technique was
employed for the sample preparation in this work and
provides high recoveries of the drugs. A good internal
standard must mimic the analyte during extraction and
compensate for any analyte on the column. Isotope-labeled
analyte was not available to serve as the IS, so, in the initial
stages of this work, several compounds were investigated to
ﬁnd a suitable IS and ﬁnally carbamazepine was found to bebest for the present purpose. Carbamazepine was evaluated
for precision and accuracy and extraction recovery of the
internal standard was good and reproducible.
3.3. Selectivity and chromatography
The degree of interference by endogenous plasma constitu-
ents with the analytes and the IS was assessed by inspection
of chromatograms derived from processed blank plasma
sample. As shown in Figs. 2 and 3 no signiﬁcant direct
interference in the blank plasma traces was observed from
endogenous substances in drug-free plasma at the retention
time of the analytes and the IS.
3.4. Sensitivity
The lowest limit of reliable quantiﬁcation for the analytes
was set at the concentration of the LLOQ. The precision
and accuracy at LLOQ concentration were found to be
4.35% and 101.89% for telmisartan, 7.59% and 103.35%
for amlodipine.
3.5. Matrix effect
No signiﬁcant matrix effect was observed in all the eight
batches of human plasma for the analytes at LQC and HQC
concentrations. The precision and accuracy for telmisartan at
LQC concentration were found to be 1.66% and 100.30% and
at HQC level they were 0.37% and 99.94%, respectively.
Similarly, the precision and accuracy for amlodipine at LQC
concentration were found to be 1.69% and 102.52%, and at
HQC level they were 1.12% and 100.12%, respectively.
3.6. Linearity
Ten-point calibration curve was found to be linear over the
concentration range of 2.01–400.06 ng/mL for telmisartan and
0.05–10.01 ng/mL for amlodipine. After comparing the two
weighting models (1/x and 1/x2), a regression equation with a
weighting factor of 1/x2 of the drug to the IS concentration
was found to produce the best ﬁt for the concentration–
detector response relationship for both the analytes in human
plasma. The mean correlation coefﬁcient of the weighted
calibration curves generated during the validation was 0.99.
3.7. Precision and accuracy
Accuracy and precision data for intra- and inter-day plasma
samples for telmisartan and amlodipine are presented in
Table 1. The assay values on both the occasions (intra- and
inter-day) were found to be within the accepted variable limits.
3.8. Extraction efﬁciency
A simple solid-phase extraction with Oasiss HLB 1 cm3
(30 mg) extraction cartridge was proved to be robust and
provided cleanest samples. The recoveries of analytes and the
IS were good and reproducible. The mean overall recoveries
(with the precision range) of telmisartan, amlodipine and the
Figure 2 Typical MRM chromatograms of telmisartan (left panel) and the IS (right panel) in human blank plasma (A), and human
plasma spiked with IS (B), a LLOQ sample along with IS (C).
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4.50%) and 78.3370.85% (2.13–2.36%), respectively.
3.9. Dilution integrity
The upper concentration limits can be extended to 640.09 ng/
mL for telmisartan and 16.02 ng/mL for amlodipine by 1/2
and 1/4 dilutions with screened human blank plasma. The
mean back-calculated concentrations for 1/2 and 1/4 dilution
samples were within 85–115% of their nominal value. The
coefﬁcients of variation (%CV) for 1/2 and 1/4 dilution
samples were less than 15%.
3.10. Stability studies
In the different stability experiments carried out, viz. bench
top stability (10 h), autosampler stability (48 h), freeze-thaw
stability (4 cycles), reinjection stability (24 h), wet extract
stability (40 h at 2–8 1C) and long-term stability at –70 1C
for 30 days, the mean % nominal values of the analytes were
found to be within 715% of the predicted concentrations forthe analytes at their LQC and HQC levels (Table 2). Thus, the
results were found to be within the acceptable limits during the
entire validation.
Stock solutions of telmisartan, amlodipine and the IS were
found to be stable for 10 days at 2–8 1C. The percentage
stability (with the precision range) of telmisartan, amlodipine
and the IS was 103.02% (1.20–2.21%), 99.44% (1.30–1.63%)
and 102.27% (2.29–2.58%), respectively.3.11. Pharmacokinetic study results
In order to verify the sensitivity and selectivity of this method
in a real-time situation, the present method was used to test
for telmisartan and amlodipine in human plasma samples
collected from healthy male volunteers (n¼6). The mean
plasma concentration vs time proﬁle of telmisartan (presented
up to 24 h in order to depict the plot with clarity) and
amlodipine is shown in Fig. 4(A) and (B), respectively and
the pharmacokinetic data are listed in Table 3. These values
were in close proximity when compared with earlier reported
values [14,21].
V.B. Ravi et al.3244. Discussion
To date, no reports are available for the simultaneous quantiﬁca-
tion of telmisartan and amlodipine in any of the matrices.
Validated methods are essential for the determination ofFigure 3 Typical MRM chromatograms of amlodipine (left panel) a
plasma spiked with IS (B), a LLOQ sample along with IS (C).
Table 1 Precision and accuracy of the method for determining t
Analyte Concentration
added (ng/mL)
Intra-day precision and accurac









Amlodipine 0.05 0.05 11.84
0.15 0.15 3.98
5.04 5.02 0.63
8.54 8.31 2.54telmisartan and amlodipine concentrations in human plasma
for bioequivalence studies. This is, to the best of our knowledge,
the ﬁrst validation report for an LC–MS/MS method for the
simultaneous assay of telmisartan and amlodipine using the
simple solid-phase extraction procedure. The reported method isnd the IS (right panel) in human blank plasma (A), and human
elmisartan and amlodipine in plasma samples.
y Inter-day precision and accuracy









100.10 2.03 5.66 99.27
99.91 5.99 2.27 99.51
99.75 200.40 0.74 99.80
100.02 345.80 4.53 101.61
105.91 0.05 10.73 101.44
99.63 0.15 3.47 100.43
99.67 5.01 0.99 99.53
97.26 8.36 2.72 97.84
Table 2 Stability samples result for telmisartan and amlodipine in human plasma (n¼6).






















(at 10 1C for 48 h)
6.02 5.4270.37 90.03 6.75 0.15 0.1570.01 101.64 5.20
340.32 340.5371.51 100.06 0.44 8.54 8.4870.08 99.28 0.92
Wet extract stability
(at 2-8 1C for 40 h)
6.02 5.72 70.23 94.95 3.97 0.15 0.1670.01 104.63 3.74
340.32 338.8872.31 99.58 0.68 8.54 8.4770.06 99.24 0.76
Bench top stability
(10 h)
6.02 5.9870.22 99.31 3.62 0.15 0.1570.01 100.58 3.64
340.32 340.1271.85 99.94 0.54 8.54 8.5170.08 99.64 0.92
Freeze–thaw stability 6.02 6.05 70.11 100.35 1.78 0.15 0.1470.01 95.93 4.20
340.32 340.5671.20 100.07 0.35 8.54 8.3870.14 98.14 1.65
Reinjection stability
(24 h)
6.02 6.05 70.13 100.10 2.18 0.15 0.1570.01 101.09 3.55
340.32 340.0971.41 99.86 0.41 8.54 8.5170.07 102.00 0.86
Long-term stability (at
70 1C for 30 days)
6.02 5.8670.26 96.96 4.48 0.15 0.1570.01 100.43 6.92
340.32 340.0071.95 99.83 0.57 8.54 8.4670.10 101.44 1.19
Figure 4 Mean plasma concentration–time proﬁle of telmisartan
(A), and amlodipine (B), in human plasma following the oral
administration of 80/10 mg ﬁxed dose combination of telmisartan
and amlodipine tablet to healthy volunteers (n¼6).
Table 3 Pharmacokinetic parameters of telmisartan and
amlodipine (n¼6, Mean7SD).
Parameter Telmisartan Amlodipine
tmax (h) 0.8870.14 8.0070.63
Cmax (ng/mL) 364.66742.11 6.1870.56
AUC0–t (ng h/mL) 1137.717324.97 270.63762.03
AUC0–inf (ng h/mL) 1139.107325.39 335.167103.30
t1/2 (h) 10.4773.48 35.31714.17
Kel (h1) 0.0770.03 0.0270.01
Simultaneous LC–MS/MS quantiﬁcation of telmisartan and amlodipine in human plasma 325simple, rugged and rapid due to utilization of short run time of
2.5 min for each sample analysis.5. Conclusions
The LC–MS/MS assay reported in this paper is rapid, simple,
speciﬁc and sensitive for simultaneous quantiﬁcation of telmi-
sartan and amlodipine in human plasma and is fully validated
according to commonly acceptable FDA guidelines. The method
showed suitability for pharmacokinetic studies in humans. The
cost-effectiveness, simplicity of the assay and usage of solid phase
extraction, and sample turnover rate of less than 2.5 min per
sample, make it an attractive procedure in high-throughput
bioanalysis of telmisartan and amlodipine. From the results of
all the validation parameters, we can conclude that the developed
method can be useful for BA/BE studies and routine therapeutic
drug monitoring with the desired precision and accuracy.Acknowledgments
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